

Sanofi: access to *diabetes education*



Over 536 million adults are estimated to live with diabetes globally and 1.1 million children (under the age of 19) live with type 1 diabetes (T1D)^{1,2}



More than 90% of people living with diabetes have type 2 diabetes (T2D)¹



Insulin therapy requires self-monitoring of blood glucose, comprehensive diabetes education, and the support of skilled health professionals¹



Studies show improvement in blood sugar control in people with diabetes following participation in education programs^{3, 4}

Kids and Diabetes in Schools (KiDS)

KiDS is an initiative launched in 2013 to foster a school environment that creates better understanding of diabetes and supports children with diabetes through a range of resources.


Partnership with Sanofi, International Diabetes Federation (IDF) and International Society for Pediatric and Adolescent Diabetes (ISPAD).²

KiDS targets children (aged 6-14), parents, teachers, school doctors, policymakers, and government officials.²


Objectives:

- Tackle diabetes-related stigmatisation
- Support children with T1D to manage their condition at school
- Highlight preventable risk factors for T2D
- Promote healthier lifestyles to a younger audience

KiDS global impact



KiDS program in Goa, India



Explore more at kids.idf.org

Sanofi's commitment to education, patient support and access to medication programs

Sanofi supported diabetes programs are helping to address unmet needs around access and education across the world, to support people living with diabetes to improve their management and give them a better understanding of their own disease. Additionally, they provide educators, healthcare professionals and carers with a better understanding of diabetes.

To date, Sanofi supports multiple programs worldwide, focusing on these areas:



Educational programs



Patient support programs



Access focused programs

Examples of educational programs:

Time in Range (TiR) Academy⁷

Objective: a program for healthcare professionals on the relevance of TiR and its use as a glycemic metric to inform treatment decisions, and enhance self-management for people living with diabetes.

DIGUAN⁸

Objective: a program with a digital platform, targeted at adolescents with T1D, to support them with the self-management of their disease. *1 in 3* adolescents with T1D reached from 2013 to 2022 in Spain.

Our ambition is to *enable better diabetes care* around the world through access to sustainable solutions, and to *improve the quality of life for people living with diabetes, no matter where they live*. This is a shared responsibility with local health systems, and we are committed to play our part.

References: 1. International Diabetes Federation. IDF Diabetes Atlas Tenth Edition. <https://diabetesatlas.org/> Accessed: October 2022. 2. IDF Kids. Kids and Diabetes in Schools. <https://kids.idf.org/kids-and-diabetes-in-schools/> Accessed: October 2022. 3. Essien O, et al. PLoS ONE 12 (January 2017), e0168835, <https://doi.org/10.1371/journal.pone.0168835> 4. Brady EM, et al. BMJ Open 11 (August 2021), e047425, <https://doi.org/10.1136/bmjopen-2020-047425> 5. IDF Kids. Success Stories. <https://kids.idf.org/success-stories>. Accessed: October 2022. 6. Sanofi Diabetes LMIC Support Programs Mapping Report. Accessed October 2022. 7. Time in Range Academy. TiR Academy Home. <https://www.tiracademy2022.com/home> Accessed: October 2022. 8. Diguan: Una visión del programa educativo tras 9 años de experiencia. <https://www.diguan.es>. Accessed October 2022.
© Sanofi Australia and New Zealand, Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113
+61 2 8666 2000 MAT-AU-2203133 Prepared November 2022